MedTrace Logo

Evaluation of The Performance of Retinow AI Software

NCT06645964 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 915

Last updated 2024-10-17

No results posted yet for this study

Summary

Eye diseases are a major public health problem worldwide and one of the main causes of vision loss. Diseases such as diabetic retinopathy, glaucoma and macular degeneration in particular can lead to serious vision loss and negatively affect quality of life. Early diagnosis of these diseases, determination of appropriate treatment methods and protection of patients' quality of life are of great importance.

In recent years, artificial intelligence (AI) technologies have offered great opportunities for disease diagnosis and management in the medical field. Artificial intelligence algorithms developed for retinal image analysis have become an effective tool in the early diagnosis of eye diseases such as diabetic retinopathy, glaucoma and macular degeneration. Ophthalmic imaging and scanning systems supported by AI technology facilitate the diagnosis of these diseases and contribute to the treatment processes.

Artificial intelligence can provide an effective solution for automatic diagnosis of this disease and prediction of disease progression. Retinow AI was developed to accelerate early diagnosis of these three important eye diseases (diabetic retinopathy, glaucoma, macular degeneration), increase access and reduce costs. This software aims to provide a solution to the shortage of ophthalmologists and the limitations of existing methods. Retinow AI's ability to diagnose these diseases with high sensitivity and accuracy through fundus photographs is being evaluated within the scope of clinical research. According to the hypothesis, the software's accuracy rate can reach 90%, thus speeding up clinical processes and reducing the workload of healthcare personnel. In addition, it is planned to be used as an effective screening tool in regions where ophthalmologists are insufficient.

Conditions

Sponsors & Collaborators

  • Retinow Health Technologies and R&D Industry Joint Stock Company

    lead OTHER

Principal Investigators

  • Tuğba Haklı Piroğlu, Master · Authorized Representative

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2023-10-01
Completion
2023-10-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06645964 on ClinicalTrials.gov